tacrolimus and Periodontitis

This study was to investigate the effect of tacrolimus (FK506) on periodontitis induced in rats.. Periodontal disease was induced in 30 Wistar rats which were then randomly divided into two groups: treatment with a daily injection of 0.9% saline (1mL/day) and treatment with a daily injection of FK506. After periods of 10, 15 and 30days the animals were killed and separate radiographs of the right and left hemimandibles were obtained. One calibrated examiner measured the periodontal bone support (PBS) in the images, after the following treatments: S, saline without ligature; SL, saline with ligature; T, FK506 without ligature; TL, FK506 with ligature. The data were subjected to analysis of variance (ANOVA) and the Tukey test (p<0.01).. The radiographic results were similar at all evaluation time points. The S treatment had a higher PBS averaging at 10, 15 and 30days, which was statistically significant different compared with the SL treatment and TL treatment, but not significantly different from the T treatment. The SL and TL treatments showed no statistically significant differences between them.. Tacrolimus used for up to 30days showed no protective or aggravating effects on alveolar bone loss.

Topics: Alveolar Bone Loss; Animals; Disease Models, Animal; Ligation; Male; Periodontitis; Random Allocation; Rats; Rats, Wistar; Tacrolimus

To compare oral health status between renal transplant recipients (RTRs) receiving tacrolimus (Tac) or everolimus (ERL) as immunosuppressive therapy.. This study is a cross-sectional study.. Thirty-six RTRs receiving Tac and 22 RTRs receiving ERL were included in the study. Age, gender, time since transplant and pharmacological data were recorded for both groups. Oral health status was assessed through the evaluation of teeth, periodontal parameters as well as saliva flow rate and pH.. RTRs receiving ERL were older than those receiving Tac. No differences were found between groups concerning oral hygiene habits, oral symptoms, smoking habits, unstimulated and stimulated saliva flow rate and pH, clinical attachment level or the number of decayed, missing and filled teeth. However, RTRs receiving ERL presented lower visible plaque index and lower values for bleeding on probing when compared to RTRs receiving Tac. In addition, RTRs receiving ERL presented a gingival index varying from normal to moderate inflammation whereas RTRs receiving Tac presented a gingival index varying from mild to severe inflammation.. RTRs receiving ERL have lower periodontal inflammation when compared to RTRs receiving Tac.

Topics: Adolescent; Adult; Age Factors; Aged; Allografts; Cross-Sectional Studies; Dental Plaque Index; DMF Index; Everolimus; Female; Gingival Hemorrhage; Health Status; Humans; Hydrogen-Ion Concentration; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Oral Health; Oral Hygiene; Periodontal Attachment Loss; Periodontal Index; Periodontitis; Saliva; Secretory Rate; Sirolimus; Smoking; Tacrolimus; Young Adult

Periodontitis is a well-appreciated example of leukocyte-mediated bone loss and inflammation with pathogenic features similar to those observed in other inflammatory diseases, such as arthritis. Since Tacrolimus, is an immunomodulatory drug used for the treatment of some cases of arthritis, we hypothesized that it may modulate periodontal disease.. Using a murine model of ligature-induced periodontal disease, we assessed the effects of daily administrations of Tacrolimus (1mg/kg body weight) on bone loss, enzymatic (myeloperoxidase) analysis, differential white blood cells counts, airpouch exudate and cytokine expression for 5-30 days.. Radiographic, enzymatic (myeloperoxidase) and histological analysis revealed that Tacrolimus reduced the severity of periodontitis. More specifically, Tacrolimus suppressed the expression of serum interleukin (IL-1beta), tumour necrosis factor (TNF-alpha), IL-6, airpouch exudate PGE(2) and leukocytosis usually observed after the induction of periodontitis. Tacrolimus treatment in periodontitis-induced rats conferred protection against the inflammation-induced tissue and bone loss associated with periodontitis, through a mechanism involving IL-1beta, TNF-alpha and IL-6.. The effects of Tacrolimus on periodontal disease pathogenesis may provide clues to a novel approach to host modulation therapy in destructive periodontal disease.

Topics: Alveolar Bone Loss; Animals; Calcineurin Inhibitors; Dinoprostone; Disease Models, Animal; Gingiva; Immunologic Factors; Immunosuppressive Agents; Interleukin-1beta; Interleukin-6; Leukocyte Count; Leukocytosis; Male; Periodontitis; Peroxidase; Rats; Rats, Wistar; Tacrolimus; Time Factors; Tumor Necrosis Factor-alpha